Storyline
FDA starts/accepts review of BMS “celmod” in multiple myeloma as other decisions diverge
Two reports converged on a key U.S. regulatory step for Bristol Myers Squibb: the FDA has started/accepted review of the company’s “celmod” protein degrader for multiple myeloma.
Published 2026-02-18 13:02 UTCUpdated 2026-02-18 19:58 UTC
Current brief openSource links open
This current storyline is open here with summary, metadata, source links, continuity context, and full evidence. Paid is for compare-over-time, alerts, exports, and workflow.
No card needed for the free brief.
Evidence trail (top sources)
top sources (2 domains)domains are deduped. counts indicate coverage, not truth.2 top sources shown
limited source diversity in top sources
Overview
Two reports converged on a key U.S. regulatory step for Bristol Myers Squibb: the FDA has started/accepted review of the company’s “celmod” protein degrader for multiple myeloma.
Score total
1.27
Momentum 24h
3
Posts
3
Origins
2
Source types
2
Duplicate ratio
33%
Why now
- Both items were published within the last day and focus on fresh FDA/EMA actions
- BMS review milestone is highlighted by two outlets in the same news cycle
- Roundup format bundled multiple regulatory updates into one briefing
Why it matters
- FDA review initiation/acceptance is a gating step toward a potential U.S. approval
- Roundup underscores simultaneous wins/setbacks shaping near-term regulatory outlook
- EMA approval noted for a heart-disease therapy signals continued EU decision flow
Continuity snapshot
- Trend status: insufficient_history.
- Continuity stage: emerging_confirmed.
- Current status: open.
- 3 current source-linked posts are attached to this storyline.
All evidence
All evidence
FDA accepts BMS protein degrader for review; Disc rare disease drug rejected
BioPharma Dive · biopharmadive.com · 2026-02-18 15:35 UTC
FDA starts review of BMS's 'celmod' for multiple myeloma
pharmaphorum · pharmaphorum.com · 2026-02-18 13:02 UTC
Show filters & breakdown
Posts loaded: 0Publishers: 2Origin domains: 2Duplicates: -
Showing 2 / 0
Top publishers (this list)
- BioPharma Dive (1)
- pharmaphorum (1)
Top origin domains (this list)
- biopharmadive.com (1)
- pharmaphorum.com (1)